» Articles » PMID: 37773074

Clinical, Morphologic, and Molecular Features of Benign and Intermediate-grade Melanocytic Tumors With Activating Mutations in MAP2K1

Abstract

Activating mutations in MAP2K1 can be seen in benign and intermediate-grade melanocytic neoplasms with spitzoid morphology. We analyzed the clinical, histopathologic, and genetic features for 16 cases of benign and intermediate-grade melanocytic tumors harboring activating MAP2K1 mutations. We compared them to Spitz neoplasms with characteristic Spitz fusions or HRAS mutation. We also compared the mutational pattern of benign and intermediate-grade MAP2K1 -mutated neoplasms and melanomas with activating MAP2K1 mutations. Among the 16 cases, the favored morphologic diagnosis was Spitz nevus (8/16), atypical Spitz tumors (6/16), and deep penetrating nevus (2/16). The 2 most common architectural patterns seen included a plaque-like silhouette with fibroplasia around the rete reminiscent of a dysplastic nevus (n=7) or a wedge-shaped or nodular pattern with the plexiform arrangement of the nests aggregating around the adnexa or neurovascular bundle (n=8). The cases with dysplastic architecture and spitzoid cytology resembled dysplastic Spitz nevi. Compared with true Spitz neoplasms, MAP2K1 -mutated neoplasms occurred in older age groups and had more frequent pagetosis and a lower average mitotic count. The most common type of mutation in the benign and intermediate-grade cases in the literature involves an in-frame deletion, while, in melanomas, missense mutations are predominant. Benign and intermediate-grade melanocytic neoplasms with activating mutations in MAP2K1 can have morphologic overlap with Spitz neoplasms. A significant proportion of melanomas also have activating MAP2K1 mutations. In-frame deletions are predominantly seen in the benign and intermediate-grade cases, and missense mutations are predominantly seen in melanomas.

Citing Articles

Role of Targeted Sequencing in Routine Diagnostics of Spitz Melanocytic Neoplasms-An Analysis of 70 Cases.

Sekoranja D, Zupan A, Matjasic A, Bostjancic E, Calonje E, Pizem J J Cutan Pathol. 2024; 52(2):141-153.

PMID: 39511946 PMC: 11710898. DOI: 10.1111/cup.14750.


Gene Expression Profile of Benign, Intermediate, and Malignant Spitz and Spitzoid Melanocytic Lesions.

Giubellino A, He Y, Munro S, Zhou Y, Song K, Plaza J Cancers (Basel). 2024; 16(10).

PMID: 38791877 PMC: 11119593. DOI: 10.3390/cancers16101798.


Spitz Melanocytic Tumors: A Fascinating 75-Year Journey.

Chatzopoulos K, Syrnioti A, Linos K Genes (Basel). 2024; 15(2).

PMID: 38397186 PMC: 10887813. DOI: 10.3390/genes15020195.


Spitz Tumors and Melanoma in the Genomic Age: A Retrospective Look at Ackerman's Conundrum.

Urso C Cancers (Basel). 2023; 15(24).

PMID: 38136379 PMC: 10741987. DOI: 10.3390/cancers15245834.